AU2001242952A1 - Atherosclerosis vaccine - Google Patents
Atherosclerosis vaccineInfo
- Publication number
- AU2001242952A1 AU2001242952A1 AU2001242952A AU4295201A AU2001242952A1 AU 2001242952 A1 AU2001242952 A1 AU 2001242952A1 AU 2001242952 A AU2001242952 A AU 2001242952A AU 4295201 A AU4295201 A AU 4295201A AU 2001242952 A1 AU2001242952 A1 AU 2001242952A1
- Authority
- AU
- Australia
- Prior art keywords
- dialdehyde
- tcr
- interacting
- chains
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 abstract 4
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 abstract 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 229940118019 malondialdehyde Drugs 0.000 abstract 2
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an antigenic composition capable of eliciting antibodies by interacting with alphabeta chains of a T cell receptor (TcR), which composition is comprised of a peptide-aldehyde conjugate. The aldehyde portion may be a dialdehyde, such as malondialdehyde (MDA), or a monoaldehyde, such as 4-hydroxynonenal (4-HNE), while the peptide portion preferably comprises at least one lysine residue. The antigenic composition according to the invention is capable of recognizing and interacting with a TcR having a complementarity-determining region 3 (CDR3) of alpha10 and beta6 chains that comprises a cluster of charged and polar amino acids. The invention also relates to a method of producing a vaccine against atherosclerosis by screening of a library of candidate compounds for their ability to bind to a conjugate of oxidized LDL and a dialdehyde as well as to such a vaccine as such.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000855A SE0000855D0 (en) | 2000-03-15 | 2000-03-15 | Antigenic composition useful as a vaccine against atherosclerosis |
| SE0000855 | 2000-03-15 | ||
| PCT/SE2001/000570 WO2001068119A1 (en) | 2000-03-15 | 2001-03-15 | Atherosclerosis vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001242952A1 true AU2001242952A1 (en) | 2001-09-24 |
Family
ID=20278814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001242952A Abandoned AU2001242952A1 (en) | 2000-03-15 | 2001-03-15 | Atherosclerosis vaccine |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040002111A1 (en) |
| EP (1) | EP1335742B1 (en) |
| AT (1) | ATE401907T1 (en) |
| AU (1) | AU2001242952A1 (en) |
| DE (1) | DE60135010D1 (en) |
| DK (1) | DK1335742T3 (en) |
| SE (1) | SE0000855D0 (en) |
| WO (1) | WO2001068119A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355664A4 (en) * | 2001-01-04 | 2005-10-26 | Vascular Biogenics Ltd | Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| SE0103754L (en) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide |
| US20030105003A1 (en) * | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| JP2005504085A (en) | 2001-09-28 | 2005-02-10 | エスペリオン セラピューティクス，インコーポレイテッド | Prevention and treatment of restenosis by local administration of drugs |
| SE0302422D0 (en) * | 2003-09-11 | 2003-09-11 | Forskarpatent I Syd Ab | Peptide-based immunization therapy for the treatment of atherosclerosis |
| JP2007531537A (en) | 2004-04-06 | 2007-11-08 | セダーズ−シナイ メディカル センター | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein AI and apolipoprotein A-IMLANO |
| CA2776927C (en) * | 2004-04-15 | 2014-08-12 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| JP5654446B2 (en) * | 2008-04-10 | 2015-01-14 | ザ・トロンボシス・リサーチ・インスティテュートＴｈｅ Ｔｈｒｏｍｂｏｓｉｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | Anti-atheroma vaccine |
| WO2012038922A1 (en) * | 2010-09-22 | 2012-03-29 | Hansson Goeran K | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
| US8609605B2 (en) | 2009-03-17 | 2013-12-17 | Cardiovax, Llc | Immunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100 |
| CU23736A1 (en) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | ANTIBODIES RECOGNIZING SULFATIDES AND SULFATED PROTEOGLYCANS AND THEIR USE |
| WO2011060329A1 (en) * | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| EP2637689A2 (en) | 2010-11-12 | 2013-09-18 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| JP2013544243A (en) | 2010-11-12 | 2013-12-12 | シーダース シナイ メディカル センター | Immunomodulation method and system for treatment and / or prevention of aneurysm |
| CA2843960C (en) | 2011-08-09 | 2020-09-15 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| DK2742068T3 (en) | 2011-08-09 | 2019-06-11 | Athera Biotechnologies Ab | NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE |
| EP3484284A1 (en) * | 2016-07-12 | 2019-05-22 | Kymab Limited | Animals, cells, ligands, polypeptides & methods |
| WO2018236909A1 (en) * | 2017-06-20 | 2018-12-27 | La Jolla Institute For Allergy And Immunology | Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis |
| WO2023240120A2 (en) * | 2022-06-07 | 2023-12-14 | La Jolla Institute For Immunology | Novel treatments for cardiovascular related disease |
-
2000
- 2000-03-15 SE SE0000855A patent/SE0000855D0/en unknown
-
2001
- 2001-03-15 EP EP01916008A patent/EP1335742B1/en not_active Expired - Lifetime
- 2001-03-15 AU AU2001242952A patent/AU2001242952A1/en not_active Abandoned
- 2001-03-15 DK DK01916008T patent/DK1335742T3/en active
- 2001-03-15 AT AT01916008T patent/ATE401907T1/en not_active IP Right Cessation
- 2001-03-15 US US10/221,573 patent/US20040002111A1/en not_active Abandoned
- 2001-03-15 DE DE60135010T patent/DE60135010D1/en not_active Expired - Lifetime
- 2001-03-15 WO PCT/SE2001/000570 patent/WO2001068119A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001068119A1 (en) | 2001-09-20 |
| EP1335742A1 (en) | 2003-08-20 |
| SE0000855D0 (en) | 2000-03-15 |
| US20040002111A1 (en) | 2004-01-01 |
| EP1335742B1 (en) | 2008-07-23 |
| DK1335742T3 (en) | 2008-11-17 |
| ATE401907T1 (en) | 2008-08-15 |
| DE60135010D1 (en) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001242952A1 (en) | Atherosclerosis vaccine | |
| WO1995029193A3 (en) | Melanoma antigens | |
| EP0677533A3 (en) | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof | |
| EP2311952A3 (en) | Antibodies to MRT-1 protein or fragments thereof | |
| GB9712512D0 (en) | A method for in vitro molecular evolution of protein function | |
| AU3117201A (en) | Methods and compositions for generating human monoclonal antibodies | |
| PL344190A1 (en) | Novel method for the production of anti-human antigen receptors and uses thereof | |
| EP1264890A3 (en) | Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays | |
| WO2004022594A3 (en) | Immune modulatory compounds and methods | |
| AU676859B2 (en) | Synthetic peptides, antibodies against them and their use | |
| WO1998022510A3 (en) | Methods for the production of chicken monoclonal antibodies | |
| DE69114339T2 (en) | Methods for identifying or determining proteins and uses therefor. | |
| WO1999058678A3 (en) | Antibodies to dendritic cells and human dendritic cell populations and uses thereof | |
| WO2002008716A3 (en) | Method for screening peptides for use in immunotherapy | |
| WO1999013907A3 (en) | Methods to improve immunogenicity of antigens and specificity of antibodies | |
| ES534510A0 (en) | A METHOD FOR DETERMINING THE PRESENCE OF A NATURAL SEQUENCE OF AMINO ACID REMAINS OF A PROTENOID. | |
| Rüdiger et al. | Monoclonal antibody ID5: epitope characterization and minimal requirements for the recognition of polyglutamylated α-and β-tubulin | |
| AU2003283240A1 (en) | Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells | |
| HK1063057A1 (en) | Pharmaceutical composition of f(ab) 2 fragments of antibodies and method for the preparation thereof | |
| WO2004039842A3 (en) | Humanized tissue factor antibodies | |
| CA2441187A1 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same | |
| EP0806478A3 (en) | p53as Protein and antibody therefor | |
| WO1994002508A3 (en) | Polypeptide antigens of mycobacterium bovis | |
| WO2001047953A3 (en) | Antibodies against plasma cells | |
| WO2000019207A3 (en) | Method for identifying atrial natriuretic peptide (anp) |